Drug Trial Radar · NCT06046222
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Conditions
- Eosinophilic Granulomatosis With Polyangiitis
- Churg-Strauss Syndrome
Interventions
NS-229Drug
Experimental
PlaceboDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects in remission [OGC 4.0]Time frame: From Baseline to week 28
Locations
34 sites in 8 countries. Site status is shown where the registry gives one.
National Jewish Health
Denver, Colorado
Mayo Clinic
Rochester, Minnesota
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
University of Alberta
Edmonton, Alberta, Canada
St Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
University of Toronto
Toronto, Ontario, Canada
CHU Nice
Nice, France
Hopital Cochin
Paris, France
Chu Rangueil
Toulouse, France
Medius Kliniken gGmbh
Kirchheim unter Teck, Studienzentrale, Germany
Istituto Auxologico Italiano IRCCS
Milan, Italy
Fondazione Policlinico Universitario Campus Bio-Medico
Roma, Italy
Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento
Trento, Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy
Chiba University Hospital
Chuo-ku, Chiba-shi, Chiba, Japan
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu, Fukuoka, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
NHO Sagamihara National Hospital
Sagamihara, Kanagawa, Japan
National Hospital Organization Yokohama Medical Center
Yokohama, Kanagawa, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Osaka Habikino Medical Center
Habikino, Osaka, Japan
Saitama Medical Center
Kawagoe, Saitama, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Kyorin University Hospital
Mitaka, Tokyo, Japan
Toho University Omori Medical Center
Ōta-ku, Tokyo, Japan
Complejo Hospitalario de Navarra
Pamplona, Spain
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, A Coruna, Spain
Addenbrookes Hospital
Cambridge, United Kingdom
Royal Berkshire NHS Foundation Trust
Reading, United Kingdom
Queen Elizabeth Hospital Birmingham
Edgbaston, Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.